Immune Pharmaceuticals Inc. has entered into an exclusive license with Atlante Biotech SAS to the patents and know-how for a new format of bispecific antibodies. “This is an important milestone as we make progress with our immuno-oncology pipeline,” said Daniel Teper, chief executive officer, Immune Pharmaceuticals. “Our research will focus on the application of this novel bispecific platform to target immune checkpoints. Our plan is to generate additional pre-clinical data with selecte...